Cheshire, UK--(Marketwire - August 13, 2007) -
Protherics PLC
Notification of Director's Interests
London, UK; Brentwood, TN, US: 13 August 2007 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that Rolf
Soderstrom, who was appointed as Finance Director of the Company on 10
August 2007, has been granted options to subscribe for 423,076 ordinary
shares in the Company under the terms of the Company's Long-Term
Incentive Plan. The options were granted on 10 August 2007 and are
exercisable between the third and tenth anniversary of the date of grant
at a price of 2p per ordinary share, subject to the achievement of
performance conditions.
The current issued ordinary share capital of the Company is 339,243,653
shares.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange